Bullish
How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook
UroGen Pharma recently announced strong Phase 3 data for UGN-103, showing 94.5% six-month durability in bladder cancer, similar to their approved drug...